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Abstract
Background: A significant number of young people start smoking at an age of 13-15, which means that serious
smoking-evoked changes may have been occurred by their twenties. Surfactant proteins (SP) and matrix
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) have been linked to cigarette smoke induced lung
remodelling and chronic obstructive pulmonary disease (COPD). However, the level of these proteins has not been
examined during ageing or in young individuals with short smoking histories.
Methods: Plasma levels of SP-A, SP-D, MMP-9, and TIMP-1 were measured by EIA/ELISA from young (18-23 years)
non-smoking controls (YNS) (n = 36), smokers (YS) (n = 51), middle aged/elderly (37-77 years) non-smoking
controls (ONS) (n = 40), smokers (OS) (n = 64) (FEV1/FVC >0.7 in all subjects) and patients with COPD (n = 44,
35-79 years).
Results: Plasma levels of SP-A increased with age and in the older group in relation to smoking and COPD. Plasma
SP-D and MMP-9 levels did not change with age but were elevated in OS and COPD as compared to ONS. The
TIMP-1 level declined with age but increased in chronic smokers when compared to ONS. The clearest correlations
could be detected between plasma SP-A vs. age, pack years and FEV1/FVC. The receiver operating characteristic
(ROC) curve analysis revealed SP-A to be the best marker for discriminating between patients with COPD and the
controls (area under ROC curve of 0.842; 95% confidence interval, 0.785-0.899; p < 0.001).
Conclusions: Age has a significant contribution to potential markers related to smoking and COPD; SP-A seems to
be the best factor in differentiating COPD from the controls.
Background
Smoking is the major risk factor for the development of
chronic obstructive pulmonary disease (COPD), and
smoking cessation is the only effective way to slow
down disease progression [1-3]. Young people generally
start smoking at 13-15 years of age, which means that
s i g n i f i c a n tc h a n g e sd u et os m o k i n gm a yh a v eb e e n
occurred within 10 years i.e. by the time they are 25
years, they may have suffered the damage which will
later develop into COPD. There is a need to devise sen-
sitive and specific markers for early COPD, but at
present, the tests are unreliable. In this study, we mea-
sured plasma levels of surfactant protein A (SP-A), sur-
factant protein D (SP-D), matrix metalloproteinase-9
(MMP-9) and tissue inhibitor of matrix metalloprotei-
nase-1 (TIMP-1) in young and middle aged/elderly smo-
kers and in patients with COPD. The selection of these
potential marker compounds was based on previous stu-
dies on COPD, i.e. either non-hypothesis/proteomics
(SP-A) or hypothesis driven (SP-D, MMP-9) studies,
which have indicated that especially these markers may
predict COPD, its development and/or progression
[4-9]. These compounds have never been compared pre-
viously in one single investigation.
Pulmonary surfactant is a mixture of phospholipids
and proteins formed mainly by type II pneumocytes
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and play important and unique roles in pulmonary
defense against inflammation/oxidative stress [11,12].
The surfactant composition and functions have been
found to be modulated by smoking and/or COPD
[13-16], and most studies in this field have reported ele-
vated levels of SP-A in the serum of the patients with
COPD [6,8]. Serum SP-D has been postulated to be a
potential marker for COPD, being able to predict both
exacerbations and response to corticosteroid therapy
[17-20]. Surfactants have also been found to regulate the
balance of proteases/antiproteases through different
pathways, SP-A may even regulate MMP-9 production
and function [21-24]. One of the most widely suggested
hypothesis in the pathogenesis of COPD involves an
imbalance between proteases and antiproteases [4,25].
Matrix metalloproteinases cleave components of the
extracellular matrix and basement membranes and the
balance of their activities is strictly controlled by their
inhibitors. The changes in these proteases, especially
MMP-9 and its major endogenous inhibitor TIMP-1,
have been strongly linked to smoking and COPD
[4,5,26,27]. However, little is known about whether
there are age related alterations in these proteins in
smokers and/or COPD.
The main goal of this study was to find out whether
smoking and ageing affect the levels and relationships
between circulating SP-A, SP-D, MMP-9 and TIMP-1.
T h es e c o n dp u r p o s ew a st od e t e r m i n ew h e t h e rt h e
levels of these markers would be associated with demo-
graphic parameters and lung function values in young
and middle aged/elderly smokers, as well as in COPD
patients in comparison to their age-matched controls.
None of the subjects had any other environmental expo-
sures, all COPD cases were newly diagnosed, and had
no other diagnosed diseases nor were they taking any
medications.
Methods
Subjects and samples
Plasma samples were collected from middle aged/elderly
subjects who had been contacted from the Division of
Pulmonary Medicine, Lapland Central Hospital [28] and
from young smokers and non-smokers who were mili-
tary draftees from the Northern Command of the Fin-
nish Defence Forces [29]. Details of these cohorts have
been described in the abovementioned studies [28,29].
Based on self-reported detailed questionnaire all subjects
were symptom-free and considered themselves as
healthy, they had no other environmental exposures
(such as second hand smoke, pollutants or asbestos
fibres) [28]. The study population included young (age <
25 years) healthy smokers (YS), young non-smoking
healthy controls (YNS), middle-aged/elderly healthy
smokers (OS) and non-smoking healthy controls (ONS),
and patients with stable COPD (Stage I-III). The diagno-
sis of COPD was defined according to the Global Strat-
egy for the diagnosis, management and prevention of
COPD (GOLD) criteria; FEV1 < 80% of predicted, FEV1/
FVC < 70% and bronchodilatation effect < 12% [2,30].
Spirometric values were assessed by standard spirometry
(Medriko M 904, Kuopio, Finland) and the Finnish
reference values for spirometry [31]. Exclusion criteria
included allergies, asthma, a history of respiratory dis-
ease, or respiratory infection less than 8 weeks before
entering the study. None of the subjects had any other
diagnosed disease or any medications. The study was
approved by the Ethics Committee of Lapland Central
Hospital (4
th June 2003 and 31
st October 2006) and all
participants provided written informed consent.
The measurement of SP-A, SP-D, MMP-9 and TIMP-1
Plasma samples were randomly chosen from the cohorts
that represented the various sub-groups for the study.
SP-A and SP-D levels were measured by commercially
available EIA/ELISA kits (SP-A test Kokusai-F kit, Sys-
m e x ,K o b e ,J a p a n ;S P - Dk i tY a m a s aE I Ak i t ,Y a m a s a
Co., Chiba, Japan) as described [6,32]. MMP-9 and
TIMP-1 levels were determined by commercially avail-
able ELISA kits (Amersham Biosciences, Cardiff, UK)
according to the manufacturers’ instructions. The detec-
tion limits of SP-A and SP-D were 1.0 ng/ml and 17.2
ng/ml, respectively and for MMP-9 and TIMP-1 0.6 ng/
ml and 1.25 ng/ml, respectively.
Statistical analysis
The data are given as means together with standard
deviation (SD). All statistical analyses were performed
with the SPSS 18.0 software program (SPSS Inc., Chi-
cago, IL). The analyses of variance (ANOVA) and t-test
for independent groups were used to evaluate the statis-
tical significances between the study groups. Linear mul-
tivariate regression analysis was used to study the
independent effect of age, smoking status and COPD to
SP-A, SP-D, MMP-9 and TIMP-1. Correlations between
the variables were determined with the Pearson correla-
tion coefficient. Due to the pair wise comparisons, a
p-value of <0.01 was considered statistically significant.
SP-A, SP-D, MMP-9 and TIMP-1 levels were further
analyzed for their predictive capability to distinguish
patients with COPD from the control subjects (YNS and
ONS) according to receiver operating characteristic
(ROC) curves.
Results
Subjects and lung function characteristics
The characteristics of the subjects are shown in Table 1.
All young and middle aged/elderly smokers and non-
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GOLD criteria (post bronchodilator FEV1/FVC > 0.7)
[30]. In the COPD group, there were 15 patients with
stage I, 24 patients with stage II and 5 patients with
stage III COPD according to the GOLD classification.
All COPD cases were newly diagnosed and were taking
no regular medications.
The level of SP-A increases with ageing, smoking, and
COPD
Plasma level of SP-A increased with age in non-smokers
and smokers (p < 0.0001 and p < 0.0001), respectively.
In young non-smokers (YNS), the mean values were
22.2 ± 6.0 ng/ml, and in middle aged/elderly non-smo-
kers they were 31.4 ± 10.6 ng/ml, the corresponding
mean values in YS being 23.0 ± 6.8 ng/ml and OS 43.3
± 17.5 ng/ml. This latter finding may be partly related
to the longer smoking history of OS. Cigarette smoke
had no significant effect on the SP-A levels in the young
age group, with their relatively short smoking histories.
In the older age group, plasma SP-A was higher in OS
when compared to ONS (p < 0.0001). Importantly,
plasma SP-A was also higher in COPD (55.4 ± 24.6 ng/
ml) compared to OS (p = 0.009), and ONS (p < 0.0001)
(Figure 1A). The linear regression analysis confirmed
that age (regression coefficient (B) = 6.01, standard
error (SE) = 2.54, p = 0.019), cigarette smoking (B =
0.45, SE = 0.07, p < 0.001) and COPD (B = 17.08, SE =
3.67, p < 0.001) had independent effects on SP-A level.
The level of SP-D does not change with ageing but is
elevated in OS and COPD compared to ONS
Plasma level of SP-D did not change with age, i.e. the
mean levels in YNS and ONS (109.0 ± 62.3 ng/ml and
106.0 ± 41.2 ng/ml) were similar. Furthermore there
was no difference between YNS and YS. In the older
group, the levels were higher in OS (156.2 ± 90.2 ng/ml)
and COPD (186.3 ± 101.9 ng/ml) when compared to
ONS (p = 0.012 and p < 0.0001) but there was no signif-
icant difference between OS and COPD (Figure 1B).
COPD patients had even higher levels of SP-D (B =
64.72, SE = 19.53, p = 0.001) when adjusted for age with
linear multivariate regression analysis.
The level of MMP-9 is elevated in OS and COPD
compared to ONS
The plasma concentrations of MMP-9 were very similar
in YNS and ONS (47.1 ± 49.1 and 44.4 ± 34.6 ng/ml)
and there was no significant difference between YNS
and YS. In the older age group, the levels were higher in
OS (86.5 ± 40.8 ng/ml) compared to ONS (p < 0.0001).
The level of MMP-9 was significantly higher in COPD
than in ONS (p = 0.033). The MMP-9 results are sum-
marized in Figure 1C. Linear regression analysis revealed
that both age (B = 0.44, SE = 0.19, p = 0.022) and cigar-
ette smoking (B = 26.0, SE = 6.91, p < 0.0001) had inde-
pendent effects on the MMP-9 level.
The levels of TIMP-1 and MMP-9/TIMP-1 increase in
response to long-term smoking
The plasma level of TIMP-1 declined with age (p =
0.03), but there was no significant difference between
Y N Sa n dY S .I nt h eo l d e rg r o u p ,t h eT I M P - 1l e v e l s
were higher in OS (117.7 ± 18.2 ng/ml) and COPD
(114.9 ± 23.5 ng/ml) than in ONS (81.3 ± 26.6 ng/ml, p
< 0.001 and p = 0.001), but there was no significant dif-
ference between OS and COPD (Figure 1D). The ratio
of MMP-9 to TIMP-1 did not change with age. In addi-
tion, there were no significant differences between YNS
and YS. In the older group, the MMP-9/TIMP-1 ratio
was higher in OS (0.79 ± 0.3) than in ONS (0.28 ± 0.2,
p < 0.0001) indicative of a significant protease/antipro-
tease imbalance in favor of proteases. In addition, the
linear regression analysis confirmed the independent
Table 1 The characteristics of the patients
Variable Young Middle aged/elderly
Non-smokers Smokers Non-smokers Smokers COPD
Number 36 51 40 64 44
Age (yr) 19.5 (0.8) 20.0 (1.0) 53.3 (8.8) 52.1 (8.0) 61.3 (8.5)
Sex (F/M) 2/34 1/50 28/12 24/40 9/35
Pack-years - 5.1 (2.3) - 30.4 (14.3) 39.8 (15.0)
BMI 24.1 (2.5) 24.1 (3.1) 26.5 (4.2) 27.7 (4.0) 26.9 (3.8)
Post- bronchodilator
FVC (l)
5.5 (0.8) 5.5 (0.8) 3.8 (0.8) 4.0 (0.9) 3.8 (0.9)
FEV1 (l) 4.8 (0.7) 4.8 (0.7) 3.2 (0.6) 3.3 (0.7) 2.3 (0.7)
FEV1
(% predicted)
97.3 (6.1) 100.1 (9.5) 104.7 (13.6) 95.3 (12.2) 70.0 (16.8)
FEV1/FVC 87.6 (5.6) 87.1 (4.8) 84.5 (5.9) 82.7 (5.1) 60.6 (9.3)
COPD: chronic obstructive pulmonary disease; BMI: body mass index; FVC: forced vital capacity; FEV1: forced expiratory volume in one second. Data is shown as
mean (SD).
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0.018) and MMP-9/TIMP-1 (B = 4.01, SE = 0.15, p =
0.014).
Significant correlations can be seen especially with SP-A
Figures 2, 3 and 4 show how SP-A, SP-D and MMP-9
are related to age, pack years, BMI and lung functions
in different study groups. The clearest correlations
could be seen with plasma SP-A vs. age, pack years and
FEV1/FVC (Figure 2A-D), though some correlations
could also be observed with SP-D (Figure 3A-D). The
plasma MMP-9 level correlated only with age and pack
years, though some minor correlations could be seen
with all these parameters and BMI (Figure 4A-D).
The levels of SP-A also correlated with SP-D (r = 0.36,
p < 0.0001).
Receiver Operating Characteristic (ROC) curve analysis is
most accurate for SP-A
ROC curve analysis was carried out to evaluate the sen-
sitivity, specificity and diagnostic accuracy of plasma
SP-A, SP-D, MMP-9 and TIMP-1. The areas under the
ROC curve were as follows: for SP-A: 0.845 (95%
confidence interval (CI), 0.787 to 0.902, p < 0.001); for
SP-D: 0.734 (95% CI, 0.636 to 0.883, p < 0.001); for
MMP-9: 0.551 (95% CI, 0.450 to 0.652, p = 0.320) and
for TIMP-1: 0.664 (95% CI, 0.516 to 0.813, p = 0.051)
(Figure 5).
Figure 1 Box-and-whisker plots of SP-A, SP-D, MMP-9 and TIMP-1 in plasma (A, B, C and D, respectively). The boxes represent the 25th
to 75th percentiles, the solid lines within the boxes show the median values, the whiskers are the 10th and 90th percentiles, and the points
represent outliers. *: p < 0.05; **: p < 0.01; ***: p < 0.001 (between two groups, t-test).
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The present study evaluated plasma levels of SP-A, SP-
D, MMP-9 and TIMP-1 in young and middle aged/
elderly non-smokers and smokers, and patients with
COPD. All of these putative markers have been sug-
gested to associate with COPD. When these potential
parameters were evaluated, SP-A appeared to be the
most promising marker for COPD since its levels were
elevated after long-term smoking and also in COPD as
compared to the situation in chronic smokers. SP-A was
also clearly correlated with age, pack years and airway
obstruction. However, it remains unclear whether SP-A
can be used as a marker for COPD or its development.
The levels of none of these proteins were changed due
to smoking in the group of young smokers who had
relatively short smoking histories, no diseases or other
exposures and normal values in spirometry.
The elevation of plasma SP-A by smoking/COPD is in
agreement with previous investigations though there are
many controversial findings as well. Plasma/serum SP-A
levels have been reported to be elevated in COPD in a
Japanese cohort of smokers and patients with COPD
Figure 2 Relationship between plasma SP-A levels and the demographic parameters, age (A), BMI (B), pack-years (C) and FEV1/FVC%
of predicted (D), in all of the subjects. ○ = young non-smokers; ● = young smokers; ◊ = middle aged/elderly non-smokers; ♦ = middle
aged/elderly smokers; ■ = COPD patients.
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are in line with other investigations of the levels of SP-
A in the circulating blood [33-36]. In a recent proteomic
study of pulmonary tissue, SP-A was found to be one of
the most markedly elevated spots when investigated by
two dimensional electrophoresis, i.e. its presence in the
spots was confirmed by mass spectrometry [8]. There
are some opposite findings with respect to the circulat-
ing SP-A levels in smokers and/or COPD determined in
serum [20,37], lung tissue [38] or bronchoalveolar lavage
(BAL) [15,16,39]. In some of those studies, SP-A had
been either investigated by a non-quantitative immuno-
histochemical technique or from BAL, which is proble-
matic due to its invasive nature and collapse of the
airways in COPD. Very few studies have investigated the
effect of age on the levels of potential plasma biomar-
kers, this report has concentrated on these changes,
especially with respect to SP-A, since these may be
Figure 3 Relationship between plasma SP-D levels and the demographic parameters, age (A), BMI (B), pack-years (C) and FEV1/FVC%
of predicted (D), in all of the subjects. ○ = young non-smokers; ● = young smokers; ◊ = middle aged/elderly non-smokers; ♦ = middle
aged/elderly smokers; ■ = COPD patients.
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tion in all corresponding investigations.
Genotype and age of the patients have been shown to
have an influence on the SP-A levels [40,41] and some
SP-A alleles may increase the risk for development of
COPD [42]. In the study of Ohlmeier [8], SP-A was
confirmed to represent SP-A2, but the assay used in the
present study is known to detect both SP-A1 and SP-A2
isoforms. Further studies will be necessary to investigate
the long term changes in plasma SP-A levels, and also if
SP-A1 and SP-A2 predict disease progression or
whether these changes are related to smoking alone.
SP-D has been proposed to represent a marker for
COPD, especially predicting its exacerbations [17]. How-
ever, there are studies indicating that serum SP-D is not
changed [6] in smokers/COPD or that its levels in BAL
are reduced in smokers [15,16,43] and patients with
COPD [44]. In the present study, plasma SP-D levels
did not differ between the young and old age groups;
neither were they different between OS and COPD.
Figure 4 Relationship between plasma MMP-9 levels and the demographic parameters, age (A), BMI (B), pack-years (C) and FEV1/FVC
% of predicted (D), in all of the subjects. ○ = young non-smokers; ● = young smokers; ◊ = middle aged/elderly non-smokers; ♦ = middle
aged/elderly smokers; ■ = COPD patients.
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showing no significant changes in lung tissue SP-D in
COPD [8]. Overall, SP-D revealed only slight variability,
possibly some elevation due to smoking, but the changes
were smaller than those observed with SP-A.
MMP-9 and TIMP-1 have been postulated to be asso-
ciated with COPD and its development [4,5,26,27]. This
was the reason why MMP-9 and TIMP-1 were included
in the present study. This study confirms previous
investigations that the MMP-9 level is increased in
long-term smokers [5,45], but as far as we are aware,
there are no studies which have investigated the levels
of MMP-9 or TIMP-1 in different age groups of non-
smokers or smokers. This study detected no significant
d i f f e r e n c ei np l a s m aM M P - 9b e t w e e nY N Sa n dY Sb u t
as shown earlier, the changes observed in MMP-9 and
TIMP-1 were mostly attributable to smoking. These
data also suggest that short-term smoking (<10 years) in
young healthy subjects does not significantly modify the
levels of circulating MMP-9 or TIMP-1. However, long-
term smoking (>10 years) increased both plasma levels
of MMP-9 and MMP-9/TIMP-1, perhaps reflecting
increased systemic inflammation, though active remo-
delling in the airways is evidently more prominent.
Since there are multiple MMPs and TIMPs, the MMP-
9/TIMP-1 ratio alone does not reflect the overall pro-
tease/antiprotease balance in the lung. Many studies
have been conducted on MMPs and the protease/anti-
protease balance in COPD, but it is still unclear if these
changes predict COPD in the longitudinal setting.
The weakness of this study is that in the young age
group, most of the individuals were men. Therefore we
compared the results between the genders in the middle
aged/elderly group but could detect no significant differ-
ences between the genders with respect to the levels of
SP-D, MMP-9 or TIMP-1. Only the plasma SP-A level
Figure 5 Receiver operating characteristic curves of SP-A, SP-D, MMP-9 and TIMP-1 in plasma (A, B, C and D, respectively) obtained
from patients with COPD, young and middle aged/elderly smokers and the controls. Values in parentheses indicate 95% confidence
intervals for the area under the curve (AUC).
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ing women when compared to the men (p = 0.012).
This was also a cross-sectional study, and therefore the
value of these proteins in COPD will require further
prospective investigations. This study has significant
strengths i.e. none of the non-smokers or smokers had
any other exposures. The chronic smokers suffering
from COPD, were taking no medications for COPD
s i n c et h e yh a dn e w l yd i a g n o s e dC O P Da n dn o n eo f
them had any other diseases or were taking any medica-
tions. This does not exclude the existence of cardiovas-
cular or other organ involvements, though all subjects
considered themselves as healthy [28].
Conclusions
In conclusion, the plasma level of SP-A may be a pro-
mising marker for COPD, it displayed age related
changes and exhibited a significant elevation due to
smoking, but prospective studies will be needed to eluci-
date the significance of SP-A and also potential new
markers of COPD. Two prospective studies are ongoing
in our laboratory [28,46], where potential markers are
being evaluated and will be tested within the next two
and five years. These and other potential markers may
also prove to be important in young smokers, especially
when evaluating early lung damage in cases when smok-
ing or other environmental exposures are combined
with impaired lung development and/or other abnorm-
alities of the lung.
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